[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"doc-seo-351366-105":3,"detail-sidebar-cat-0-en-105":81,"doc-detail-351366-en":131},{"code":4,"msg":5,"data":6},0,"ok",{"site_id":7,"language":8,"slug":9,"title":10,"keywords":11,"description":12,"schema_data":13,"social_meta":74,"head_meta":76,"extra_data":78,"updated_unix":80},105,"en","splice-switching-of-the-oncogenic-bcs1l-isoform-suppresses-ovarian-cancer-progression-by-disrupting-mitochondrial-function","Splice-switching of the oncogenic BCS1L isoform suppresses ovarian cancer progression by disrupting mitochondrial function","","Increasing evidence shows mitochondrial function is essential for cancer cell survival and metastasis, yet mitochondrial metabolic reprogramming in ovarian cancer progression remains unclear. This article reports that the mitochondrial chaperone BCS1L produces two alternative-spliced isoforms, BCS1L-L and BCS1L-S. BCS1L-L elevates oxidative phosphorylation and ATP production, while USP39 promotes exon 2 inclusion to sustain mitochondrial homeostasis. Splice-switch antisense oligonucleotides induce exon 2 skipping, reduce BCS1L-L, and impair tumor growth.",{"@graph":14,"@context":73},[15,34,56],{"@type":16,"itemListElement":17},"BreadcrumbList",[18,23,27,31],{"item":19,"name":20,"@type":21,"position":22},"https://docshare.wps.com","Home","ListItem",1,{"item":24,"name":25,"@type":21,"position":26},"https://docshare.wps.com/document/","Document",2,{"item":28,"name":29,"@type":21,"position":30},"https://docshare.wps.com/document/research-report/","Research & Report",3,{"item":32,"name":10,"@type":21,"position":33},"https://docshare.wps.com/document/splice-switching-of-the-oncogenic-bcs1l-isoform-suppresses-ovarian-cancer-progression-by-disrupting-mitochondrial-function/351366/",4,{"url":32,"name":10,"@type":35,"image":36,"author":41,"headline":10,"publisher":44,"fileFormat":47,"inLanguage":8,"description":12,"dateModified":48,"datePublished":49,"encodingFormat":47,"isAccessibleForFree":50,"interactionStatistic":51},"DigitalDocument",{"url":37,"@type":38,"width":39,"height":40},"https://docshare.wps.com/thumbnails/splice-switching-of-the-oncogenic-bcs1l-isoform-suppresses-ovarian-cancer-progression-by-disrupting-mitochondrial-function/351366.png","ImageObject",300,407,{"name":42,"@type":43},"WPS_1786070896","Person",{"url":19,"name":45,"@type":46},"DocShare","Organization","application/pdf","2026-10-23","2026-09-22",true,{"@type":52,"interactionType":53,"userInteractionCount":55},"InteractionCounter",{"@type":54},"ViewAction",11,{"@type":57,"mainEntity":58},"FAQPage",[59,65,69],{"name":60,"@type":61,"acceptedAnswer":62},"What alternative isoforms of BCS1L are generated by splice switching?","Question",{"text":63,"@type":64},"BCS1L produces two major alternative-spliced isoforms: a full-length BCS1L-L and a short isoform, BCS1L-S, lacking exon 2.","Answer",{"name":66,"@type":61,"acceptedAnswer":67},"How does BCS1L-L influence mitochondrial metabolism in ovarian cancer cells?",{"text":68,"@type":64},"BCS1L-L localizes to mitochondria and significantly increases oxidative phosphorylation and ATP production, supporting cancer cell survival.",{"name":70,"@type":61,"acceptedAnswer":71},"How does targeting exon 2 with splice-switch antisense oligonucleotides affect tumor progression?",{"text":72,"@type":64},"Splice-switch antisense oligonucleotides induce exon 2 skipping, decrease BCS1L-L abundance, disrupt mitochondrial metabolic support, and impair tumor growth.","https://schema.org",{"og:url":32,"og:type":75,"og:title":10,"og:site_name":45,"og:description":12},"article",{"robots":77,"canonical":32},"index,follow",{"doc_id":79,"site_id":7},351366,1790798536,{"code":4,"msg":82,"data":83},"success",[84,88,92,96,101,106,111,115,120,123,127],{"id":22,"doc_module":4,"doc_module_name":25,"category_name":85,"show_sort_weight":86,"slug":87},"Story & Novel",90,"story-novel",{"id":26,"doc_module":4,"doc_module_name":25,"category_name":89,"show_sort_weight":90,"slug":91},"Literature",80,"literature",{"id":33,"doc_module":4,"doc_module_name":25,"category_name":93,"show_sort_weight":94,"slug":95},"Exam",70,"exam",{"id":97,"doc_module":4,"doc_module_name":25,"category_name":98,"show_sort_weight":99,"slug":100},5,"Comic",60,"comic",{"id":102,"doc_module":4,"doc_module_name":25,"category_name":103,"show_sort_weight":104,"slug":105},6,"Technology",50,"technology",{"id":107,"doc_module":4,"doc_module_name":25,"category_name":108,"show_sort_weight":109,"slug":110},7,"Healthcare",40,"healthcare",{"id":112,"doc_module":4,"doc_module_name":25,"category_name":29,"show_sort_weight":113,"slug":114},8,30,"research-report",{"id":116,"doc_module":4,"doc_module_name":25,"category_name":117,"show_sort_weight":118,"slug":119},9,"Religion & Spirituality",20,"religion-spirituality",{"id":118,"doc_module":4,"doc_module_name":25,"category_name":121,"show_sort_weight":118,"slug":122},"World Cup","world-cup",{"id":124,"doc_module":4,"doc_module_name":25,"category_name":125,"show_sort_weight":124,"slug":126},10,"Lifestyle","lifestyle",{"id":128,"doc_module":4,"doc_module_name":25,"category_name":129,"show_sort_weight":97,"slug":130},19,"General","general",{"code":4,"msg":82,"data":132},{"doc_id":79,"user_id":133,"nickname":42,"user_avatar":134,"doc_module":4,"category_id":112,"category_name":29,"doc_title":10,"doc_description":12,"doc_content":135,"file_id":136,"file_url":137,"file_type":138,"file_size":139,"view_count":55,"is_deleted":4,"is_public":22,"is_downloadable":22,"audit_status":22,"page_count":140,"language":141,"language_code":8,"site_id":7,"html_lang":8,"table_of_contents":142,"faqs":143,"seo_title":144,"seo_description":12,"update_tm":145,"read_time":146,"preview_page_count":33,"preview_urls":147},549768072016,"https://ap-avatar.wpscdn.com/davatar_155a257f0dc6eb9ab79c44ca47cae57d","[www.nature.com/cddis](www.nature.com/cddis)  \nARTICLE OPEN   \nSplice-switching of the oncogenic BCS1L isoform suppresses ovarian cancer progression by disrupting mitochondrial function  \nMeining Xu1,2,7, Zixiang Wang 1,2,7, Siyuan Yang1,2,7, Gaoyuan Li 1, Xiyu Zhang 1, Ling Zhao 1, Lei Yang 1, Chunhong Qiu1, Xianguang Feng3, Kai Zhang3, Bin Liu4, Jian-jun Wei 5, Yuliang Li 4 ✉, Gang Liu6 ✉, Baoxia Cui 1 ✉, Junchao Qin1,4 ✉ and Zhaojian Liu 1,2,6 ✉  \n© The Author(s) 2026  \n\n|  | Increasing evidences demonstrate that mitochondrial function is essential for cancer cell survival and metastasis. However, the role of mitochondrial metabolic reprogramming in ovarian cancer progression remains largely unknown. Here, we report that mitochondrial chaperone BCS1L generates two major alternative-spliced isoforms, a full-length isoform (BCS1L-L) and a short isoform lacking exon 2 (BCS1L-S) . Interestingly, BCS1L-L is elevated in several human cancers, and it signiﬁcantly increased oxidative phosphorylation and ATP production in the present work, which is required for the survival of cancer cells. In contrast, BCS1L-S was unable to localize to the mitochondria as BCS1L-L did, and this led to impaired metabolic function. Mechanistically, splicing factor USP39 promoted exon 2 inclusion, thus facilitating the generation of oncogenic BCS1L-L and, thereby, maintaining mitochondrial homeostasis and survival of ovarian cancer cells. Importantly, we developed splice-switch antisense oligonucleotides (ASOs) that successfully induced exon 2 skipping and decreased BCS1L-L abundance, resulting in impaired tumor growth. These ﬁndings |  |\n| --- | --- | --- |\n|  |  |  |\n|  |  |  |\n|  |  |  |\n|  |  |  |\n|  |  |  |\n|  |  |  |\n|  |  |  |\n|  |  |  |\n| suggest that targeting oncogenic BCS1L-L by ASOs is a novel approach for ovarian cancer treatment. |  |  |\n|  | Cell Death and Disease (2026)17:293; [https://doi.org/10.1038/s41419-026-08495-6](https://doi.org/10.1038/s41419-026-08495-6) |  |\n|  |  |  |\n\nINTRODUCTION  \nIncreasing evidences demonstrate that functional mitochondria are essential for cancer cells. Mitochondrial transfer from immune cells leads to tumor cell immune evasion [1] . Cancer cells can steal mitochondria from nerve cells to fuel their spread [2] . Mitochondrial oxidative phosphorylation (OXPHOS) and glycolysis cooperate to maintain the cellular energy balance, and cancer cells undergo signiﬁcant metabolic reprogramming in order to support their rapid growth, proliferation, migration, and reshape the tumor microenvironment [3] . The Warburg effect is the most-studied metabolic change in which cancer cells favor glycolysis for energy production in the presence of sufﬁcient oxygen [4] . The Warburg effect has been observed in various human cancers, including breast [5], colorectal [6], and lung cancer [7] . Reducing glycolytic energy production is mostly destined to fail as a therapeutic option [4], but emerging evidence has demonstrated that mitochondrial function is essential for cancer cells' viability, and this might be a viable therapeutic alternative [8] .  \nIncreasing evidence suggests that OXPHOS activity is upregulated in certain cancers and is associated with cancer drug resistance and metastasis [9–11] . For example, metastatic estrogen  \nreceptor-positive breast cancers are highly reliant on OXPHOS [12], and OXPHOS is upregulated in melanoma brain metastases while inhibition of OXPHOS in mouse models reduces metastases to the brain [13] . In addition, acute myeloid leukemia stem cells are reliant on OXPHOS for survival, and single-cell multiomics sequencing of ovarian cancer cells shows that both OXPHOS and glycolysis are increased [14] . It is clear, therefore, that metabolic plasticity enables cancer cells to switch between glycolysis and OXPHOS during tumorigenesis and metastasis.  \nOXPHOS is the process in which ATP is produced through the electron transport chain, which consists of four protein complexes (complexes I–IV) [1","cbCaioxNIpd0hEJW","https://ap.wps.com/l/cbCaioxNIpd0hEJW","pdf",6996417,14,"English","# Introduction\n## Mitochondria as a driver of cancer survival and metastasis\n## Metabolic reprogramming: OXPHOS, glycolysis, and the Warburg effect\n## Complex III and mitochondrial respiratory chain context\n## BCS1L function in assembling mitochondrial complex III\n# Main Findings\n## BCS1L alternative splicing generates BCS1L-L and BCS1L-S\n## BCS1L-L enhances OXPHOS and ATP production\n## USP39 promotes exon 2 inclusion to support oncogenic BCS1L-L\n## ASOs trigger exon 2 skipping and suppress tumor growth","[{\"question\":\"What alternative isoforms of BCS1L are generated by splice switching?\",\"answer\":\"BCS1L produces two major alternative-spliced isoforms: a full-length BCS1L-L and a short isoform, BCS1L-S, lacking exon 2.\"},{\"question\":\"How does BCS1L-L influence mitochondrial metabolism in ovarian cancer cells?\",\"answer\":\"BCS1L-L localizes to mitochondria and significantly increases oxidative phosphorylation and ATP production, supporting cancer cell survival.\"},{\"question\":\"How does targeting exon 2 with splice-switch antisense oligonucleotides affect tumor progression?\",\"answer\":\"Splice-switch antisense oligonucleotides induce exon 2 skipping, decrease BCS1L-L abundance, disrupt mitochondrial metabolic support, and impair tumor growth.\"}]","Splice-switching of the oncogenic BCS1L isoform suppresses ovarian cancer progression by disrupting mitochondrial function | PDF",1790093752,35,[148,152,156,160],{"page_no":22,"url":149,"width":150,"height":151},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/bef3f5c07fad1835bd4c9ea89429c9c9.webp",983,1305,{"page_no":26,"url":153,"width":154,"height":155},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/55a44100ff94fc0d6732915fbc473b32.webp",982,1304,{"page_no":30,"url":157,"width":158,"height":159},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/a0647a30a3748739ba622a7c67226bdc.webp",981,1303,{"page_no":33,"url":161,"width":162,"height":163},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/80dbf3358b718d5b616d84b9f15aa782.webp",980,1301]